structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics to Present at Jefferies Healthcare Conference
31 mai 2023 16h30 HE | Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, May 31, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
25 mai 2023 16h30 HE | Structure Therapeutics Inc.
12-week Phase 2a and Phase 1b multiple ascending dose (MAD) topline results expected to be announced in latter half of fourth quarter 2023 Ethnobridging study initiated in Japanese individuals and...
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference
18 mai 2023 16h30 HE | Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, May 18, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
11 mai 2023 16h30 HE | Structure Therapeutics Inc.
Oral GLP-1 agonist GSBR-1290 advancing into Phase 2a study in type 2 diabetes and obesity Topline data from Phase 1b multiple ascending dose and Phase 2a studies of GSBR-1290 expected in second half...
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
30 mars 2023 16h30 HE | Structure Therapeutics Inc.
Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290Topline data from Phase 1b and Phase 2a studies of GSBR-1290 expected in 2H 2023Completed $185.3 million upsized initial public...
TIP_link_300x300.jpg
Pulmonary Arterial Hypertension Market Worth ($10.88 Billion by 2028) Lead by Asia Pacific Region (6.5% CAGR) – Global Report by The Insight Partners
28 févr. 2023 09h03 HE | The Insight Partners
New York, Feb. 28, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Pulmonary Arterial Hypertension Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and...
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
07 févr. 2023 16h00 HE | Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
structure_inline_fullcolor_rgb_12in@300ppi.png
硕迪生物宣布经增发的首次公开募股的定价
02 févr. 2023 20h59 HE | Structure Therapeutics Inc.
加利福尼亚州旧金山和中国上海, Feb. 03, 2023 (GLOBE NEWSWIRE) -- 硕迪生物技术有限公司(纳斯达克股票代码:GPCR)是一家临床阶段的全球化生物制药公司,致力于口服小分子药物的创新研发以治疗代谢性和肺部疾病。今日,公司宣布其经增发的首次公开募股的定价。公司拟发行10,740,000股美国存托股票(ADS),每股ADS代表三股普通股,公开发行价格为每股ADS...
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Announces Pricing of Upsized Initial Public Offering
02 févr. 2023 19h41 HE | Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small...